About Vasopore
Vasopore works on an active intravascular drug delivery platform. Its stated vision is to become a global leader in this field. The aim is therapies for patients with vascular disease that are safer, more effective and more durable, and that need only minimally invasive procedures.
The company is based at 1580 Oakland Road in San Jose, California. Showmean Steve Wu is the chief executive officer. Udayan Patel is an executive officer and a director.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| Jul 14, 2026 | Oct 28, 2026 | $1,100,000of $2.5M target | 13 | $84,615 | Options, Securities on exerciseRule 506(b) | Form D ↗ |
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Why Investors Backed Vasopore
Vasopore, Inc. is a San Jose company working on intravascular drug delivery. Its stated vision is to become a global leader in an active delivery platform of this kind. It wants minimally invasive therapies for vascular disease that are safer, more effective and more durable.
Who backs it
The company has sold $1.1 million of a $2.5 million offering to 13 investors. No lead investor or named backer has been announced.
We wrote this summary from public statements by Vasopore and its investors. It is not investment advice.
Leadership Team
Executive officers and directors listed on Vasopore's Form D filed Oct 28, 2026.